Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.670
-0.140 (-3.67%)
Aug 14, 2025, 2:32 PM - Market open
Prime Medicine Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 53.8 | 182.48 | 41.57 | 187.62 | 185.42 | 36.98 | Upgrade
|
| Short-Term Investments | 47.95 | 7.97 | 80.09 | 106.3 | 84.2 | 16.35 | Upgrade
|
| Cash & Short-Term Investments | 101.75 | 190.44 | 121.67 | 293.92 | 269.62 | 53.33 | Upgrade
|
| Cash Growth | -37.53% | 56.53% | -58.61% | 9.01% | 405.59% | 516.72% | Upgrade
|
| Prepaid Expenses | 3.03 | 6.78 | 19.06 | 2.45 | 0.96 | 0.07 | Upgrade
|
| Other Current Assets | 16.39 | 14.67 | 2.25 | 0.25 | - | - | Upgrade
|
| Total Current Assets | 121.29 | 211.89 | 142.98 | 296.62 | 270.58 | 53.4 | Upgrade
|
| Property, Plant & Equipment | 144.03 | 71.56 | 36.6 | 48.55 | 15.68 | 0.6 | Upgrade
|
| Other Long-Term Assets | 13.69 | 14.06 | 14.28 | 15.14 | 15.6 | 0.79 | Upgrade
|
| Total Assets | 279.01 | 297.51 | 193.85 | 360.31 | 301.86 | 54.78 | Upgrade
|
| Accounts Payable | 6.38 | 11.35 | 19.54 | 4.33 | 1.44 | 0.25 | Upgrade
|
| Accrued Expenses | 11.04 | 11.82 | 10.23 | 9.02 | 36.19 | 0.74 | Upgrade
|
| Short-Term Debt | - | - | - | - | - | 17.52 | Upgrade
|
| Current Portion of Leases | 7.26 | 3.61 | 9.28 | 11.69 | 7.34 | - | Upgrade
|
| Current Unearned Revenue | 8.32 | 7.09 | - | - | - | - | Upgrade
|
| Other Current Liabilities | 1.12 | 4.08 | 17.38 | 1.67 | 13.02 | 0.93 | Upgrade
|
| Total Current Liabilities | 34.11 | 37.96 | 56.42 | 26.71 | 57.98 | 19.44 | Upgrade
|
| Long-Term Leases | 112.48 | 37.18 | 4.36 | 17.05 | 3.07 | - | Upgrade
|
| Long-Term Unearned Revenue | 59.56 | 63.22 | - | - | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | - | 0.28 | 1.24 | 1.87 | Upgrade
|
| Other Long-Term Liabilities | 12 | 6 | - | - | - | - | Upgrade
|
| Total Liabilities | 218.15 | 144.36 | 60.78 | 44.04 | 62.3 | 21.31 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | - | - | Upgrade
|
| Additional Paid-In Capital | 852.56 | 840.36 | 624.41 | 609.85 | 15.16 | 8.35 | Upgrade
|
| Retained Earnings | -791.69 | -687.21 | -491.33 | -293.2 | -171.38 | -6.01 | Upgrade
|
| Comprehensive Income & Other | -0.01 | 0 | -0.02 | -0.38 | -0.03 | - | Upgrade
|
| Total Common Equity | 60.86 | 153.15 | 133.07 | 316.27 | -156.24 | 2.34 | Upgrade
|
| Shareholders' Equity | 60.86 | 153.15 | 133.07 | 316.27 | 239.56 | 33.47 | Upgrade
|
| Total Liabilities & Equity | 279.01 | 297.51 | 193.85 | 360.31 | 301.86 | 54.78 | Upgrade
|
| Total Debt | 119.74 | 40.79 | 13.63 | 28.75 | 10.41 | 17.52 | Upgrade
|
| Net Cash (Debt) | -17.99 | 149.65 | 108.03 | 265.18 | 259.21 | 35.81 | Upgrade
|
| Net Cash Growth | - | 38.52% | -59.26% | 2.30% | 623.80% | 314.17% | Upgrade
|
| Net Cash Per Share | -0.14 | 1.26 | 1.19 | 7.82 | 19.98 | 13.57 | Upgrade
|
| Filing Date Shares Outstanding | 131.1 | 127.66 | 115.2 | 88.4 | 17.06 | 24.32 | Upgrade
|
| Total Common Shares Outstanding | 131.02 | 127.66 | 92.64 | 88.36 | 17.06 | 24.32 | Upgrade
|
| Working Capital | 87.18 | 173.93 | 86.55 | 269.9 | 212.6 | 33.96 | Upgrade
|
| Book Value Per Share | 0.46 | 1.20 | 1.44 | 3.58 | -9.16 | 0.10 | Upgrade
|
| Tangible Book Value | 60.86 | 153.15 | 133.07 | 316.27 | -156.24 | 2.34 | Upgrade
|
| Tangible Book Value Per Share | 0.46 | 1.20 | 1.44 | 3.58 | -9.16 | 0.10 | Upgrade
|
| Machinery | 32.36 | 29.29 | 24.16 | 19.67 | 5.42 | 0.64 | Upgrade
|
| Construction In Progress | 0.23 | 3.58 | 5.4 | 1.61 | - | - | Upgrade
|
| Leasehold Improvements | 7.91 | 5.14 | 0.58 | 0.56 | 0.13 | - | Upgrade
|
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.